Alexza Pharmaceuticals Inc. and Biovail Laboratories International SRL have agreed to develop and commercialize Alexza's inhaled antipsychotic AZ-004 (Staccato loxapine) in the U.S. and Canada in a deal worth $130 million. (BioWorld Today)

Spectrum Pharmaceuticals has entered a co-development and commercialization agreement with TopoTarget A/S for belinostat, a histone deacetylase (HDAC) inhibitor, a deal worth a potential $350 million plus royalties on any net sales. (BioWorld Today)